Lacipil

Lacidipine, the active ingredient in Lacipil, is a calcium channel blocker presented as a tablet for oral use. It is indicated for the treatment of hypertension in adult patients. GNH USA supplies Lacipil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacidipine is a calcium channel blocker that lowers blood pressure by acting on the vascular smooth muscle. - Hypertension: reduces systemic arterial pressure and helps control high blood pressure. - Essential hypertension: provides long‑term blood pressure control in primary hypertension. - High blood pressure: assists in preventing cardiovascular complications associated with elevated blood pressure.

Lacidipine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate pain often occurring after dose initiation. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing. - Nausea: mild gastrointestinal discomfort. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Allergic reactions: rash, itching, or swelling that may indicate hypersensitivity. - Liver enzyme elevation: abnormal liver function tests. - Myocardial infarction: rare occurrence of heart attack. - Arrhythmias: irregular heart rhythms. - Stevens‑Johnson syndrome: severe skin reaction.

Before initiating Lacipil, several safety considerations should be observed. - Monitor blood pressure: ensure adequate control and avoid excessive drops. - Assess cardiovascular status: caution in patients with severe aortic stenosis or heart failure. - Review concomitant medications: avoid additive hypotensive agents without supervision. - Renal/hepatic function: adjust therapy if significant impairment is present. - Pregnancy and lactation: use only if the potential benefit justifies the risk. - Store below 25°C: keep in the original pack, protect from moisture.

Lacidipine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lacidipine plasma levels. - Other potent antihypertensives (e.g., ACE inhibitors, ARBs) used together can cause severe hypotension. - Grapefruit juice: enhances drug exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Diuretics: may increase the risk of electrolyte imbalance and hypotension. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can attenuate antihypertensive effect. - Beta‑blockers: may require dose adjustments to avoid excessive blood pressure lowering. - Digoxin: monitor for signs of toxicity due to altered renal clearance.